Comparison of SARS-CoV-2 Antibody Response After 2-Dose mRNA-1273 vs BNT162b2 Vaccines in Incrementally Immunosuppressed Patients

Jonathan Mitchell; Caoilfhionn M Connolly; Teresa Po-Yu Chiang; Jennifer L Alejo; William A Werbel; Dorry L Segev; Allan B Massie

doi:10.1001/jamanetworkopen.2022.11897

Comparison of SARS-CoV-2 Antibody Response After 2-Dose mRNA-1273 vs BNT162b2 Vaccines in Incrementally Immunosuppressed Patients

JAMA Netw Open. 2022 May 2;5(5):e2211897. doi: 10.1001/jamanetworkopen.2022.11897.

Authors

Jonathan Mitchell¹, Caoilfhionn M Connolly^{1

2}, Teresa Po-Yu Chiang¹, Jennifer L Alejo¹, William A Werbel^{1

3}, Dorry L Segev¹, Allan B Massie¹

Affiliations

¹ Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
² Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
³ Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Abstract

This cohort study compares the antispike antibody titers of the mRNA-1273 and BNT162b2 vaccines for SARS-CoV-2 in incrementally immunosuppressed patients.

Publication types

Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

2019-nCoV Vaccine mRNA-1273
Antibodies, Viral
Antibody Formation
BNT162 Vaccine
COVID-19* / prevention & control
Humans
SARS-CoV-2
Vaccines*

Substances

Antibodies, Viral
Vaccines
2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine

Abstract

Publication types

MeSH terms

Substances

Grants and funding